Treatment of experimental autoimmune uveoretinitis with peroxisome proliferator-activated receptor α agonist fenofbrate

Molecular Vision

Volumn 20, Issue , 2014, Pages 1518-1526

  Osada, Miho ^a   Sakai, Tsutomu ^a   Kuroyanagi, Kana ^a   Kohno, Hideo ^a   Tsuneoka, Hiroshi ^a  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

FENOFIBRATE; INTERLEUKIN 17; INTERLEUKIN 17 ANTIBODY; INTERLEUKIN 6; INTERLEUKIN 6 ANTIBODY; VASCULOTROPIN; ANTILIPEMIC AGENT; CYTOKINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; RETINA S ANTIGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOIMMUNE DISEASE; CELL INFILTRATION; CONTROLLED STUDY; DELAYED HYPERSENSITIVITY; DISEASE SEVERITY; DRUG EFFICACY; EXPERIMENTAL AUTOIMMUNE UVEORETINITIS; EXPERIMENTAL EYE DISEASE; IMMUNOREACTIVITY; LYMPHOCYTE PROLIFERATION; MALE; MUELLER CELL; NONHUMAN; PHOTORECEPTOR CELL; PROTEIN EXPRESSION; RAT; UVEORETINITIS; AGONISTS; ANIMAL; ANTAGONISTS AND INHIBITORS; AUTOIMMUNE DISEASES; BIOSYNTHESIS; BOVINE; CELL PROLIFERATION; CHEMICALLY INDUCED; DOSE RESPONSE; DRUG EFFECTS; DRUG REPOSITIONING; GENE EXPRESSION; GENETICS; LEWIS RAT; LYMPHOCYTE; MACROGLIA; METABOLISM; PATHOLOGY; RETINITIS; UVEITIS;

ANIMALS; ARRESTIN; AUTOIMMUNE DISEASES; CATTLE; CELL PROLIFERATION; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG REPOSITIONING; EPENDYMOGLIAL CELLS; FENOFIBRATE; GENE EXPRESSION; HYPOLIPIDEMIC AGENTS; LYMPHOCYTES; MALE; PPAR ALPHA; RATS; RATS, INBRED LEW; RETINITIS; UVEITIS;

EID: 84908662095     PISSN: None     EISSN: 10900535     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Caspi, RR. Th1 and Th2 responses in pathogenesis and regulation of experimental autoimmune uveoretinitis. Int Rev Immunol 2002; 21:197-208. [PMID: 12424843].
2. Forrester, J V, Huitinga, I, Lumsden, L, Dijkstra, CD. Marrow-derived activated macrophages are required during the effector phase of experimental autoimmune uveoretinitis in rats. Curr Eye Res 1998; 17:426-37. [PMID: 9561835].
3. Pouvreau, I, Zech, JC, Thillaye-Goldenberg, B, Naud, MC, Van Rooijen, N, de Kozak, Y. Effect of macrophage depletion by liposomes containing dichloromethylene- diphosphonate on endotoxin-induced uveitis. J Neuroimmunol 1998; 86:171-81. [PMID: 9663563].
4. Luna, JD, Chan, CC, Derevjanik, NL, Mahlow, J, Chiu, C, Peng, B, Tobe, T, Campochiaro, PA, Vinores, SA. Blood-retinal barrier (BRB) breakdown in experimental autoimmune uveoretinitis: comparison with vascular endothelial growth factor, tumor necrosis factor alpha, and interleukin-1beta-mediated breakdown. J Neurosci Res 1997; 49:268-80. [PMID: 9260738].
5. Desvergne, B, Wahli, W. Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr Rev 1999; 20:649-88. [PMID: 10529898].
6. Issemann, I, Green, S. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 1990; 347:645-50. [PMID: 2129546].
7. Issemann, I, Prince, RA, Tugwood, JD, Green, S. The peroxisome proliferator-activated receptor: retinoid X receptor heterodimer is activated by fatty acids and fibrate hypo-lipidaemic drugs. J Mol Endocrinol 1993; 11:37-47. [PMID: 8240670].
8. Lehmann, JM, Lenhard, JM, Oliver, BB, Ringold, GM, Kliewer, SA. Peroxisome proliferator-activated receptors a and y are activated by indo-methacin and other non-steroidal anti-inflammatory drugs. J Biol Chem 1997; 272:3406-10. [PMID: 9013583].
9. Forman, BM, Chen, J, Evans, RM. Hypolipidemic drugs, polyun-saturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors a and 8. Proc Natl Acad Sci USA 1997; 94:4312-4317 [PMID: 9113986].
10. Jones, DC, Ding, X, Daynes, RA. Nuclear receptor PPARa is expressed in resting murine lymphocytes: the PPARa in T and B lymphocytes is both transactivation and transrepres-sion competent. J Biol Chem 2002; 277:6838-45. [PMID: 11726654].
11. 4 pathway to inflammation control. Nature 1996; 384:39-43. [PMID: 8900274].
12. Cunard, R, DiCampli, D, Archer, DC, Stevenson, JL, Ricote, M, Glass, CK, Kelly, CJ. WY14,643, a PPARa ligand, has profound effects on immune responses in vivo. J Immunol 2002; 169:6806-12. [PMID: 12471112].
13. Delerive, P, De Bosscher, K, Besnard, S, Vanden Berghe, W, Peters, JM, Gonzalez, FJ, Fruchart, JC, Tedgui, A, Haegeman, G, Staels, B. Peroxisome proliferator-activated receptor a negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-kB and AP-1. J Biol Chem 1999; 274:32048-54. [PMID: 10542237].
14. Chinetti, G, Lestavel, S, Bocher, V, Remaley, AT, Neve, B, Torra, IP, Teissier, E, Minnich, A, Jaye, M, Duverger, N, Brewer, HB, Fruchart, JC, Clavey, V, Staels, B. PPAR-a and PPAR-y activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. Nat Med 2001; 7:53-8. [PMID: 11135616].
15. Delerive, P, Gervois, P, Fruchart, JC, Staels, B. Induction of IkBo expression as a mechanism contributing to the antiinflammatory activities of peroxisome proliferator-activated receptor-a activators. J Biol Chem 2000; 275:36703-7. [PMID: 10980195].
16. Lovett-Racke, AE, Hussain, RZ, Northrop, S, Choy, J, Rocchini, A, Matthes, L, Chavis, JA, Diab, A, Drew, PD, Racke, MK. Peroxisome proliferators-activated receptor a agonists as therapy for autoimmune disease. J Immunol 2004; 172:5790-8. [PMID: 15100326].
17. Donoso, LA, Merryman, CF, Shinohara, T, Dietzschold, B, Wistow, G, Craft, C, Morley, W, Henry, RT. S-antigen: identification of the MAbA9-C6 monoclonal antibody binding site and the uveitopathogenic sites. Curr Eye Res 1986; 5:995-1004. [PMID: 3492336].
18. Sakai, T, Kohno, H, Ishihara, T, Higaki, M, Saito, S, Matsushima, M, Mizushima, Y, Kitahara, K. Treatment of experimental autoimmune uveoretinitis with poly(lactic acid) nanopar-ticles encapsulating betamethasone phosphate. Exp Eye Res 2006; 82:657-63. [PMID: 16360654].
19. Kohno, H, Sakai, T, Kitahara, K. Induction of nestin, Ki-67, and cyclin D1 expression in Muller cells after laser injury in adult rat retina. Graefes Arch Clin Exp Ophthalmol 2006; 244:90-5. [PMID: 15983812].
20. Verwaerde, C, Naud, MC, Delanoye, A, Wood, M, Thillaye-Goldenberg, B, Auriault, C, de Kozak, Y. Ocular transfer of retinal glial cells transduced ex vivo with adenovirus expressing viral IL-10 or CTLA4-Ig inhibits experimental autoimmune uveoretinitis. Gene Ther 2003; 10:1970-81. [PMID: 14528321].
21. Inoki, T, Yamagami, S, Sakai, R, Isobe, M, Tsuru, T, Kawashima, H. Suppression of experimental autoimmune uveoretinitis by anti-alphabeta TCR monoclonal antibody. Jpn J Ophthalmol 2002; 46:518-24. [PMID: 12457910].
22. Xu, J, Storer, PD, Chavis, JA, Racke, MK, Drew, PD. Agonists for the peroxisome proliferator-activated receptor-a and the retinoid X receptor inhibit inflammatory responses of microglia. J Neurosci Res 2005; 81:403-11. [PMID: 15968640].
23. Xu, J, Chavis, JA, Racke, MK, Drew, PD. Peroxisome proliferator-activated receptor-α and retinoid X receptor agonists inhibit inflammatory responses of astrocytes. J Neuroimmunol 2006; 176:95-105. [PMID: 16764943].
24. 4 pathway to inflammation control. Nature 1996; 384:39-43. [PMID: 8900274].
25. Delerive, P, De Bosscher, K, Besnard, S, Vanden Berghe, W, Peters, JM, Gonzalez, FJ, Fruchart, JC, Tedgui, A, Haegeman, G, Staels, B. Peroxisome proliferator-activated receptor a negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-κB and AP-1. J Biol Chem 1999; 274:32048-54. [PMID: 10542237].
26. Spencer, NF, Poynter, ME, Im, SY, Daynes, RA. Constitutive activation of NF-κB in an animal model of aging. Int Immunol 1997; 9:1581-8. [PMID: 9352364].
27. Delerive, P, Gervois, P, Fruchart, JC, Staels, B. Induction of IκBα expression as a mechanism contributing to the antiinflammatory activities of peroxisome proliferator-activated receptor-α activators. J Biol Chem 2000; 275:36703-7. [PMID: 10980195].
28. Cunard, R, Eto, Y, Muljadi, JT, Glass, CK, Kelly, CJ, Ricote, M. Repression of IFN-γ expression by peroxisome proliferator-activated receptor-γ. J Immunol 2004; 172:7530-6. [PMID: 15187132].
29. Pascual, G, Fong, AL, Ogawa, S, Gamliel, A, Li, AC, Perissi, V, Rose, DW, Willson, TM, Rosenfeld, MG, Glass, CK. A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-γ. Nature 2005; 437:759-63. [PMID: 16127449].
30. Ogawa, S, Lozach, J, Benner, C, Pascual, G, Tangirala, RK, Westin, S, Hoffmann, A, Subramaniam, S, David, M, Rosenfeld, MG, Glass, CK. Molecular determinants of cross-talk between nuclear receptors and toll-like receptors. Cell 2005; 122:707-21. [PMID: 16143103].
31. Amadi-Obi, A, Yu, CR, Liu, X, Mahdi, RM, Clarke, GL, Nussenblatt, RB, Gery, I, Lee, YS, Egwuagu, CE. TH17 cells contribute to uveitis and scleritis and are expanded by IL-2 and inhibited by IL-27/STAT1. Nat Med 2007; 13:711-8. [PMID: 17496900].
32. Yoshimura, T, Sonoda, KH, Ohguro, N, Ohsugi, Y, Ishibashi, T, Cua, DJ, Kobayashi, T, Yoshida, H, Yoshimura, A. Involvement of Th17 cells and the effect of anti-IL-6 therapy in autoimmune uveitis. Rheumatology 2009; 48:347-54. [PMID: 19164426].
33. Bettelli, E, Carrier, Y, Gao, W, Korn, T, Strom, TB, Oukka, M, Weiner, HL, Kuchroo, VK. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006; 441:235-8. [PMID: 16648838].
34. Mangan, PR, Harrington, LE, O’Quinn, DB, Helms, WS, Bullard, DC, Elson, CO, Hatton, RD, Wahl, SM, Schoeb, TR, Weaver, CT. Transforming growth factor-beta induces development of the T(H)17 lineage. Nature 2006; 441:231-4. [PMID: 16 6 48837].
35. Adán, A, Mateo, C, Navarro, R, Bitrian, E, Casaroli-Marano, RP. Intravitreal bevacizumab (avastin) injection as primary treatment of inflammatory choroidal neovascularization. Retina 2007; 27:1180-6. [PMID: 18046222].
36. Tran, TH, Fardeau, C, Terrada, C, Ducos De Lahitte, G, Bodaghi, B, Lehoang, P. Intravitreal bevacizumab for refractory choroidal neovascularization (CNV) secondary to uveitis. Graefes Arch Clin Exp Ophthalmol 2008; 246:1685-92. [PMID: 186829 70].
37. Fine, HF, Zhitomirsky, I, Freund, KB, Barile, GR, Shirkey, BL, Samson, CM, Yannuzzi, LA. Bevacizumab (avastin) and ranibizumab (lucentis) for choroidal neovascularization in multifocal choroiditis Retina 2009; 29:8-12. [PMID: 18784620].
38. Wu, L, Evans, T, Saravia, M, Schlaen, A, Couto, C. Intravitreal bevacizumab for choroidal neovascularization secondary to Vogt-Koyanagi-Harada syndrome. Jpn J Ophthalmol 2009; 53:57-60. [PMID: 1918 4312].
39. Fine, HF, Baffi, J, Reed, GF, Csaky, KG, Nussenblatt, RB. Aqueous humor and plasma vascular endothelial growth factor in uveitis-associated cystoid macular edema. Am J Ophthalmol 2001; 132:794-6. [PMID: 1170 4 0 5 0].
40. β) in experimental autoimmune uveoreti-nitis: upregulation of VEGF without neovascularization. J Neuroimmunol 1998; 89:43-50. [PMID: 9726824].
41. Shirinsky, I, Polovnikova, O, Kalinovskaya, N, Shirinsky, V. The effects of fenofibrate on inflammation and cardiovascular markers in patients with active rheumatoid arthritis: a pilot study. Rheumatol Int 2013; 33:3045-8. [PMID: 23263548].